20th Jun 2019 10:38
4D pharma plc
(the "Company" or "4D")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.
The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 28 May 2019, and is available on the Company's website www.4dpharmaplc.com.
The proxy scores for the resolutions will shortly be available on the Company's website www.4dpharmaplc.com.
For further information please contact:
4D | |
Duncan Peyton, Chief Executive Officer Fay Weston, Head of Investor Relations
| + 44 (0)113 895 0130 + 44 (0)7990 381713 |
Zeus Capital Limited - Nomad and Joint Broker | +44 (0) 161 831 1512 |
Dan Bate / Jordan Warburton
| |
Bryan Garnier & Co. Limited - Joint Broker | +44 (0)20 7332 2500 |
Dominic Wilson / Phil Walker |
About 4D
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.
Related Shares:
DDDD.L